laboratori corpor america hold
aug pm et
summari clinic laboratori organ offer broad rang test servic
nation network laboratori
price-to-earnings oper ep
risk assess reflect lh leadership posit
larg matur industri broad geograph servic area
client state divers balanc
payer mix howev note uncertainti
surround reimburs rate futur regul
present modest risk compani
oct ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
aug pm stock trade
see sale rise billion
diagnost segment grow
covanc drug develop cdd
grow diagnost segment
well posit view moder
volum increas market share gain
organ basi expect cdd segment
grow high-single-digit long
run expect lh benefit growth
esoter test tend
center medicar medicaid servic
clinic laboratori test test price
cut maximum
price updat pressur
margin revenu growth lab test
compani lh howev dynam
could ultim benefit lh mani hospit
independ lab shut due price
see slight oper margin expans
result launchpad initi
continu synergi off-set
growth could come higher esoter
test volum acquisit
think larg laboratori provid
lh sustain competit advantag
due larg scale abil provid
wide varieti test solut lh
demonstr consist low organ
growth diagnost busi lh also
boost test volum recent period
acquisit hospit lab
smaller lab compani succumb
headwind think price lh loss
exclus insur like
partial off-set expand
long-term contract insur aet see
strong catalyst think lh trade
forward earn near fair valu
risk recommend target price
price pressur signific slowdown
target price
ep estim
multipl averag lh one-year rang
see posit
long-term trend diagnost also
expect diagnost compani continu
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
laboratori corpor america hold
laboratori director
corpor overview laboratori corpor america second-largest independ clinic
laboratori clinic laboratori test use medic profession routin test patient diagnosi
monitor treatment diseas decemb lh roughli primari test
facil servic site consist branch patient servic center stat
laboratori abil perform certain routin test quickli report result
physician immedi compani laboratori servic involv test bodili fluid
human tissu lh offer differ test consist routin test specialti
nich test esoter frequent administ routin test includ blood chemistri analys
urinalysi blood cell count pap test hiv test microbiolog cultur procedur well alcohol
substanc abus test compani esoter test includ test infecti diseas
allergi diagnost genet ident oncolog averag million specimen
process per week decemb routin test result gener avail within hour
lh provid test servic broad rang health care provid includ independ physician
hospit hmo manag care group well government institut
singl client account net sale test servic bill parti
physician author person order test payor direct patient
includ insur compani manag care organ august lh acquir medtox
scientif million decemb lh acquir orchid cellmark part agreement
ftc lh divest orchid govern patern busi june lh acquir clearston
central lab global provid central laboratori servic late stage clinic trial april lh
acquir westcliff lab ftc lost court rule tri block deal decemb lh
acquir genzym genet unit genzym corpor million august lh acquir
monogram bioscienc provid molecular diagnost test februari lh acquir nwt inc
provid drug abus test juli lh acquir dsi lab expand oper southwest
florida may compani acquir esoterix inc provid specialti refer test
februari lh bought us lab locat irvin ca
corpor strategi februari lh acquir covanc cvd billion consist
cash lh share cvd share cvd lead contract research organ cro
provid outsourc drug develop servic world-wide pharmaceut biotech medic
devic industri cro industri grow around annual low-single-digit growth
see clinic laboratori industri histor major compon growth clinic lab
industri lh acquir laboratori high fixed-cost compon oper
laboratori make acquir consolid lab attract avenu growth enabl
expans oper margin view howev think pauciti sizabl clinic lab
remain acquir therefor think lh must focu growth area one lh primari
growth strategi continu expand esoter test capabl gener
profit routin test compon strategi partner enter variou
agreement diagnost compani develop esoter diagnost test compani esoter
lab includ center molecular biolog patholog locat research triangl nc nation
genet institut lo angel ca viro-m lab minneapoli mn dianon system stratford
ct septemb lh acquir sequenom inc market leader non-invas prenat test
women health reproduct genet million septemb lh complet
acquisit chiltern intern group specialti contract research organ billion
competit landscap clinic lab industri estim gener billion annual
revenu highli competit thousand independ clinic lab physician offic lab
hospital-bas lab lh second-largest provid lab servic enjoy leverag
competitor compani main competitor publicly-trad largest clinic lab
provid smaller competitor includ bio-refer laboratori medtox scientif
signific consolid past decad major publicli trade lab acquir
primarili lh
financi trend sale rose billion billion repres compound
annual growth rate compound-annual-growth-rate think sale driven organ growth acquisit
exclus nation laboratori contract unitedhealthcar effect januari
compani recent extend deal end think contract provid
billion billion increment sale life deal adjust ep increas
redistribut reproduct prohibit without prior written permiss copyright cfra
laboratori corpor america hold
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
lh under-valued
neutral sinc august technic indic lh
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
laboratori corpor america hold
base index
five-year market price perform aug
success elimin individu
mandat passag tax cut
job act decemb see
develop neg health care
servic provid fewer custom like
enrol insur plan start
fewer patient insur uncompens
care rate could rise hospit
facil lead lower profit
lower demand supplement health care
year date june
versu increas
composit index health
servic increas vs
increas composit index
note sector sub-industri inform base
past perform indic futur perform
reli upon
fundament outlook health care
servic sub-industri next month
neutral think servic includ
rehabilit clinic laboratori
dialysi continu benefit
trend continu pressur
trump administr reduc govern
spend turn rais
possibl medicar reimburs rate
cut repeal afford act
rollback medicaid expans
expect provid servic dialysi
rehabilit center see mix
util increas drug price
servic provid must maintain commerci
custom base uphold profit level
custom pay higher rate
medicar
think age popul
increas focu prevent care
benefit clinic lab addit expect
increas number test per
requisit esoter test could lead
low-single-digit sale growth lab
lower outlook pharmaci benefit
manag pbm posit neutral
see lower level drug price inflat hurt
growth still high util
also see pbm continu benefit
mani brand drug lost patent
protect recent year increas
gener drug usag would increas
profit pbm
although republican administr
 difficulti repeal
stop medicaid expans think
repeal question
senat fail multipl time gather
suffici number vote pass variou
repeal replac bill howev republican
laboratori corpor america
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
laboratori corpor america hold
corpor america lh center medicar
clinic laboratori test clinic lab fee schedul clf accord
propos payment lab test would decreas major
test code receiv maximum reduct lh issu statement
question valid data use calcul propos rate see
slight neg lh given low exposur medicar reimburs
note compani like challeng propos rate court /keith
et cfra maintain buy opinion share laboratori
corpor america lh lh announc sign
definit agreement acquir chiltern specialti contract research
organ billion cash fund bank financ bond
transact subject customari close condit regulatori
approv expect close view deal
posit chiltern expand lh presenc fast-grow
oncolog therapeut area key focu pharma
industri addit chiltern focu small mid-siz client
accret lh larger biopharma client base /k snyder
et cfra maintain buy opinion share laboratori
corpor america lh rais target
ep estim premium peer reflect
improv sale growth outlook trim ep
estim lh report oper
ep vs consensu sale increas
growth diagnost partial off-set declin drug
develop due cancel two larg clinic trial late last year
expect sale growth driven recoveri drug
develop volum growth diagnost /k snyder
analyst research note compani news
corpor hold buy lh lower target
ep estim multipl
averag lh rang maintain
ep ep see lack catalyst drive
strong growth although see posit long-term trend diagnost
compani face like continu face incess price
pressur think lh trade near fair valu
corpor america lh keep target
ep estim multipl
higher end lh five-year rang ep
vs higher estim rais
ep lower ep
reduc revenu expect sale increas billion
diagnost segment revenu report increas
total volum organ tie acquisit
revenu per requisit covanc drug develop segment
revenu saw increas revenu primarili due
acquisit organ growth benefici foreign currenc translat
lh adjust oper margin declin vs
larg due implement protect access
medicar act pama mix impact acquisit chiltern
corpor america lh rais target price
ep estim premium peer
compar ten-year histor averag price-to-earnings increas
ep estim ep estim
lh report oper ep vs
consensu sale increas growth covanc drug
develop primarili driven acquisit increas
diagnost diagnost segment report increas revenu per
requisit despit neg impact pama price volum
increas organ growth acquisit growth expect
oper margin continu expand driven acquisit
addit save launchpad busi process improv initi
see sale growth strong organ growth driven
market share gain partial off-set reimburs pressur /keith snyder
corpor america lh keep target price
ep estim slight premium three-year forward
averag price-to-earnings reflect improv sale growth outlook rais
ep estim set lh report
oper ep vs consensu sale
increas growth drug develop segment driven
chiltern acquisit expect sale growth driven
acquisit volum growth diagnost partial off-set price
corpor america lh rais target
ep estim premium peer reflect increas
confid growth covanc acquisit rais
ep estim lh report
oper ep vs consensu sale
increas organ growth acquisit
diagnost covanc drug develop cdd segment perform well
respect despit headwind hurrican expect
revenu growth /keith snyder danni yang
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
laboratori corpor america hold
fiscal year analyst estim lh earn
usd quarter fiscal year lh
announc earn per share usd repres
total revenu estim fiscal year
analyst estim lh earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
laboratori corpor america hold
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
laboratori corpor america hold
